ChatGPT

The Immortality Update: Deep Research on the Most Important Discoveries and News in Longevity Sciences (Past 7 Days)

Introduction

The Immortality Update highlights cutting-edge longevity science with a focus on extending **functional life** (healthspan) rather than merely prolonging lifespan. In other words, the goal is not just more years, but healthier, high-quality years. Experts emphasize that increasing lifespan and healthspan should go hand in hand – the ultimate aim is to provide **both** longer **and** healthier lives [1]. This week's findings reflect that ethos, showcasing advances in therapies that **repair aging damage or restore function**, not just delay death. From cellular reprogramming and "young blood" therapies to new insights on inflammation and regeneration, researchers are targeting the root causes of aging to keep people living **better, not just longer**.

Key Findings: New Interventions and Discoveries in Longevity Science

Recent days brought a flurry of longevity research news. Multiple credible sources have corroborated these breakthroughs aimed at extending healthspan:

- **Partial Cellular Reprogramming Reverses Aging in Eye Cells:** *Gene therapy using three Yamanaka factors (OSK) is moving toward human trials.* Life Biosciences announced it will begin the first clinical trial of **partial epigenetic reprogramming** later this year, initially targeting age-related vision loss (optic neuropathies) [2] [3]. In animal studies, briefly turning on OSK genes in damaged eye cells **restored youthful function** without erasing cell identity [4] [5]. Older mice and even primates with glaucoma-like damage recovered vision after this treatment [6] [7]. By rejuvenating cells at the epigenetic level, this approach could **reverse cellular aging** in tissues – *for example, making old retinal cells function like younger cells* [8] [9]. The upcoming Phase 1 trial will test safety and look for functional improvements in vision [2]. If successful, partial reprogramming could emerge as a powerful regenerative therapy to **repair age-related damage** in various organs, without the cancer risk seen with full reprogramming (notably, the team omitted the oncogene **c-Myc** to improve safety [10]).

- **Plasma Exchange ("Young Blood" Dilution) Shows Human Rejuvenation Signals:** *Filtering aged blood appears to restore youthfulness in older adults.* New results from a clinical trial of **therapeutic plasma exchange (TPE)** found functional and biological anti-aging benefits [11]. In the trial led by Dr. Dobri Kiprov, participants had a portion of their old plasma removed and replaced (with albumin and saline, sometimes plus immunoglobulin). After multiple sessions, **treated patients showed improved grip strength and balance**, whereas a sham-treated control group did not [12]. Strikingly,

comprehensive aging biomarkers ("clocks") indicated a **significant reversal of biological age** in the treatment groups [11]. These findings translate earlier parabiosis research (young-old blood swapping in mice) into humans [13]. Crucially, the **rejuvenation effect seems to come from diluting pro-aging factors in old blood**, rather than needing young blood per se [14]. The trial suggested replacing aged plasma with fresh albumin **reduces systemic inflammation** and creates a signaling environment more like a younger person's [15] [11]. Scientists at the Buck Institute reported a similar TPE study where frequent plasma exchange plus IV immunoglobulin led to a **2.6-year drop in biological age** on multi-omic measures [16] [17]. While more research is needed, these results hint that periodic plasma filtration could help people **stay biologically younger and functionally stronger for longer** [18].

- **Rapamycin Rivals Diet in Extending Life (Metformin Disappoints):** *A global study in animals identifies an FDA-approved drug with geroprotective power.* Rapamycin – an immunosuppressant and mTOR inhibitor – has long been eyed as a longevity drug. A new meta-analysis (covering 167 studies in species from mice and fish to primates) confirmed that **caloric restriction** reliably prolongs life across the animal kingdom, and remarkably, **rapamycin produced similar lifespan extension** benefits [19]. In contrast, the popular diabetes drug **metformin** showed **no consistent longevity benefit** in healthy animals [20]. Researchers pooled data on both drugs and found rapamycin almost "copying" the effect of a permanent diet, boosting lifespan by comparable percentages [21] [19]. These findings, published in *Aging Cell*, reinforce rapamycin's status as a leading anti-aging candidate, while calling into question the utility of metformin alone for lifespan extension [22] [23]. Importantly, scientists caution this doesn't mean people should start taking rapamycin yet [24]. Rapamycin can have side effects (it dampens immune function), so ongoing trials are exploring optimal dosing and safety in humans [25]. Still, the meta-analysis strengthens the case that targeting nutrient-sensing pathways (like mTOR) can **mimic the anti-aging effects of fasting** – potentially offering the benefits of caloric restriction **without the diet** [26].

- **"Inflammaging" Might Not Be Inevitable – Lemur Study Challenges Aging Dogma:** *A surprising discovery in primates suggests we may prevent age-related inflammation.* Chronic low-grade inflammation with age – often called **inflammaging** – is a hallmark of human aging implicated in heart disease, dementia, and more. It's been assumed to ramp up in all aging primates, but new research on lemurs upends that idea. Duke University scientists reported that in two lemur species (ring-tailed and sifaka lemurs), **inflammatory markers *did not* increase with age at all** [27] [28]. In fact, older lemurs had similar or even slightly lower inflammation levels compared to younger ones [29]. "Neither lemur species exhibited age-related change in inflammation; if anything, older ring-tailed lemurs showed *marginal declines*," the lead researcher noted [30] [31]. This was paired with no rise in oxidative stress with age [32]. The findings – seen in multiple individuals and consistent with hints from other non-human primates – suggest that **inflammaging is not a universal feature of aging** [33] [34]. Environmental or lifestyle factors might explain why lemurs age without the chronic inflammation that plagues humans [35] [36]. This discovery raises hope that if we can identify what protects lemurs (genetically or environmentally), we might **uncouple aging from inflammation** in people. In practical terms, it opens new directions to develop interventions so that humans could age more "gracefully," avoiding the slow burn of inflammation that drives so many age-related diseases [37] [38].

- **Regenerating Hearing: Zebrafish Genes Point to Human Therapies:** *Unlocking an animal's regenerative ability could help restore senses lost in aging.* Researchers at the Stowers Institute made

headlines with a study in **Nature Communications** showing how zebrafish regrow the delicate hair cells of the inner ear – cells that, in humans, once lost (to noise or age) **never regenerate** [39]. The team identified **two specific cell-cycle genes** (distinct variants of cyclin D) that control regeneration in different supporting cell populations of the zebrafish ear [40] [41]. By selectively knocking out these genes, they showed that each gene is **required for a particular cell type to proliferate and replace lost hair cells** [42] [43]. This precise control allows zebrafish to renew their hearing cells without exhausting their stem cell pool [44] [45]. The finding is exciting because it offers **clues to how mammalian cells might be induced to regenerate**. Humans share similar cell-cycle genes, and the study authors are hopeful that understanding zebrafish regeneration could eventually enable therapies to regrow inner-ear hair cells in people [46] [47]. Such a therapy could be life-changing: age-related hearing loss and balance issues affect millions of older adults. This research is early-stage, but it demonstrates a principle that aging tissues *can* potentially be coaxed to repair themselves if we activate the right genetic programs [47] [48]. It's a step toward interventions that not only **extend lifespan** but also **restore vital functions** (like hearing and balance) that often decline with age.

Early-Stage Research vs. Clinical Trials: From Bench to Bedside

Not all longevity breakthroughs are created equal – some are still in the laboratory, while others are being tested in humans. It's crucial to distinguish **early-stage mechanisms** from actual **clinical interventions**:

- **Basic Research & Mechanistic Discoveries:** Several findings this week deepen our understanding of aging without yet providing a therapy. The **lemur inflammaging study** and the **zebrafish regeneration study** fall in this category. They reveal what *might* be possible – e.g. aging without inflammation, or regrowing cells that were thought irrecoverable – but we cannot apply these to humans **yet** [28] [46]. Still, such studies guide future strategies. For instance, identifying cyclin genes that drive regeneration in fish provides targets to try in mammalian cells [41] [42]. Likewise, discovering that primates can age without elevated inflammation suggests lifestyle or molecular tweaks that could be investigated in people [33] [38]. These insights are the **seed corn** for tomorrow's therapies.

- **Translational and Preclinical Studies:** In between lab and clinic, we have approaches like **partial reprogramming gene therapy** that are in advanced animal testing and about to enter human trials [3] [49]. Life Biosciences' OSK gene therapy (ER-100) has shown efficacy in mice and **non-human primates**, restoring visual function after optic nerve injury [6] [7]. It's now **Phase 1-ready**, aiming to treat glaucoma and related diseases in patients by late 2025 [50] [51]. This marks a transition from *promising concept* to actual clinical evaluation. Similarly, some senolytic drugs (which clear senescent cells) have moved into early human trials for diseases like osteoarthritis and Alzheimer's, based on strong animal data [52] [53]. Many metabolic modifiers (e.g. NAD boosters, fasting mimetics) are at the preclinical or supplement stage, showing healthspan benefits in lab models but awaiting rigorous trials in humans.

- **Human Trials & Functional Benefits:** Excitingly, a few longevity interventions are *already* in human testing – or even showing preliminary benefits. The **plasma exchange trials** discussed above are a prime example: these were placebo-controlled studies in people (including older adults with Alzheimer's) and reported tangible improvements (better physical function, slower cognitive decline, younger biological profiles) [11]. That pushes TPE into the realm of an **applied therapy** for age-related conditions, albeit not yet widely available. Another example is low-dose **rapamycin**: while not

yet proven to extend lifespan in humans, small trials have shown it can enhance immune response in elderly people (e.g. improving vaccine responses) without major adverse effects, hinting at healthspan benefits [25]. And as noted, larger trials are ongoing to test drugs like **metformin** in slowing multi-morbidity (the TAME trial) – though the new meta-analysis casts doubt on metformin's efficacy for lifespan, it's precisely human studies that will settle the question [23] [54]. In short, the pipeline now spans from petri dishes to patients: **dozens of longevity therapies are in or nearing clinical trials**, but only a few have reported human outcomes so far. In the words of longevity investors, we are "some years away" from the first approved anti-aging treatment, but **that horizon is getting closer** [55] as basic research graduates to human experimentation.

Technological Tools Accelerating Longevity Research

Developing true anti-aging medicine is a complex challenge – luckily, new tools are supercharging the effort. This week highlighted several **technological and methodological advances** that are helping scientists understand and intervene in aging:

- **AI and Big Data for Drug Discovery:** Artificial intelligence is playing an ever-growing role in longevity science. Researchers have created advanced **biological clocks and predictive models** that scour massive datasets for age-slowing interventions. For example, one team developed an open-source transcriptomic aging clock called **Pasta**, which analyzes gene expression patterns to measure cellular age [56] [57]. By applying this AI-driven clock to databases of ~3 million compound profiles, they identified hundreds of chemicals that either **accelerate** or **reverse** cellular aging signatures [58]. Notably, the screen flagged many chemotherapy drugs as pro-aging (which aligns with their toxic side effects) and found **rejuvenating hits** such as **HDAC inhibitors and other epigenetic modulators** that are known to promote stem cell-like states [59] [60]. The researchers experimentally validated some predictions – for instance, a compound called **piperlongumine** indeed made old cells act younger by activating stemness genes [61]. Similarly, AI-based platforms are being used to design synergistic drug combinations that target multiple hallmarks of aging at once [62] [63]. These tools dramatically speed up the search for longevity therapeutics, sifting through what would take humans decades to test. By marrying big data with biogerontology, scientists can zero in on the most promising interventions much faster than before [64] [65].

- **Next-Generation Biomarkers and Imaging:** To evaluate any longevity treatment, we need ways to measure aging and healthspan reliably. Recent advances in **biomarkers** are giving researchers "early warning systems" for aging. Multi-omics clocks (looking at epigenetic marks, transcriptomes, proteomes, etc.) can quantify biological age and track subtle rejuvenation effects in trials – as seen in the plasma exchange studies using **35 aging clocks** to detect age reversal [11]. Another example is cutting-edge medical imaging: scientists unveiled a special MRI-based brain scan that can reveal signs of accelerated aging in the brain **years or decades** before clinical symptoms of neurodegeneration appear [66]. By analyzing brain network changes in midlife adults, this tool can flag who is aging faster and might be at risk for dementia, long **before** memory loss starts [67]. Such technology could enable doctors to intervene earlier to preserve cognitive function – effectively extending one's healthspan by **preventing age-related decline** rather than reacting after the fact. Even in the lab, high-resolution cell imaging and single-cell sequencing are pinpointing where and how tissues age, guiding targeted interventions [68] [69]. In summary, new platforms – from **AI-driven discovery engines** to sophisticated clocks and scans – are empowering scientists to crack the code of aging and monitor the efficacy of longevity therapies with unprecedented precision.

Ethical and Practical Considerations: Safety, Access, and Equity

As longevity science sprints ahead, it raises important **ethical and practical questions**. Foremost is **safety** – extending life should not come at the cost of enduring harmful side effects or risks:

- **Ensuring Safety and Efficacy:** Many of these interventions are radical and relatively untested in humans, so caution is key. Gene therapies like partial reprogramming must be controlled tightly to avoid problems like cancer or loss of cell identity. (Researchers addressed this by removing the c-Myc gene from the OSKM cocktail, since c-Myc could trigger cancer – they showed rejuvenation is still possible without it [10].) Similarly, drugs that tweak fundamental pathways (like rapamycin's immune suppression) need dosing strategies that maximize benefit while minimizing harm. Encouragingly, preliminary studies suggest **low-dose, intermittent rapamycin** can be given to older adults without serious adverse effects [70], but larger trials are required before any widespread use. Another safety concern is that some gene-editing approaches (CRISPR) might cause unintended DNA damage and senescence in cells; in fact, scientists are actively working on methods to prevent CRISPR-induced cellular aging [71]. Rigorous clinical trials and long-term follow-ups will be essential to ensure that interventions truly **improve healthspan** *without* introducing new health issues.

- **Frequency, Cost, and Practicality:** Even if a therapy works, can it be delivered feasibly to millions of people? Some approaches, like therapeutic plasma exchange, currently require hospital-grade equipment and repeat sessions. Dr. Kiprov noted that to maintain benefits, TPE might need to be done 3–4 times **per year** for life [72]. This raises concerns about **scalability and cost** – few could afford quarterly plasma swaps at today's prices, and healthcare systems would struggle with the load. To succeed as longevity interventions, procedures like TPE will need to become cheaper, faster, and more accessible (or be supplemented by less invasive treatments that achieve similar effects). The same goes for cutting-edge gene therapies: they are extremely expensive at present and may initially be available to only a wealthy few. Society will need to grapple with how to ensure equitable access if "functional immortality" is on the table. There is a risk of a longevity divide, where only certain groups benefit from age-extending biotechnologies. Ethicists argue that we must prioritize interventions that can be distributed broadly – for example, **repurposed drugs** (like rapamycin) could be far more accessible globally than bespoke lab-grown stem cell treatments. Encouragingly, some longevity researchers are indeed focusing on **scalable solutions** (such as oral medications or gene therapies that can be delivered via injections) and seeking regulatory approval pathways to reach patients sooner if the evidence supports it [73] [74].

- **Ethical Use and Societal Impact:** There are also broader ethical considerations. If we extend human life significantly, what are the implications for resource allocation, retirement ages, and population? These aren't immediate concerns this week's studies answer, but they loom on the horizon. More near-term is the ethics of testing and deploying such therapies. We must ensure trials are done in diverse populations – not only to ensure treatments work for everyone (male, female, different ethnic backgrounds), but also to avoid exacerbating health disparities. The Duke lemur study, for instance, hints that environment plays a big role in aging; this underscores that social determinants (diet, pollution, stress) might need to be addressed alongside high-tech interventions to achieve equitable longevity gains [37] [75]. Finally, clear communication and managing expectations are ethical obligations. The term "immortality" is still science fiction – these advancements aim to **delay or undo aspects of aging**, but not make people live forever. It's crucial to frame them as extending the healthy years, **compressing morbidity** (so that illness and frailty are pushed to a very late

portion of life) rather than promising eternal life. Keeping this healthspan focus in mind will help society navigate the excitement responsibly, ensuring that the pursuit of longevity remains tethered to improving quality of life for all.

Future Directions and Anticipated Impact on Healthspan

This week's developments collectively paint an optimistic picture of where longevity science is headed. While challenges remain, each discovery and trial moves us closer to a world where growing older **does not mean growing ill**. In the coming years, we can expect:

- **More Therapies Entering Human Trials:** The pipeline of anti-aging interventions is only expanding. Gene therapies like Life Bio's OSK program are **on the cusp** of human testing [3] [51]. If they show safety and even modest functional benefits (e.g. improved eyesight in older patients), it will open the floodgates for applying reprogramming to other tissues (imagine rejuvenating heart cells post-heart attack, or neurons in Alzheimer's). Likewise, senolytic drugs are advancing – within the next 1–2 years we anticipate results from studies using senolytics in diseases such as Alzheimer's and kidney fibrosis, which will indicate if clearing "zombie cells" translates to tangible healthspan gains in people. The field is also awaiting data from the first large **preventative aging trials** (like the TAME trial of metformin in thousands of older adults). Even though metformin's role is debated [22] [23], the trial is a landmark as a template for how to test a drug for general aging benefits. If it or other upcoming studies succeed, it could justify *aging* as a treatable condition in the eyes of regulators.

- **Combining Interventions for Synergy:** Aging is multi-factorial, so the ultimate solution will likely be **combination therapies**. We may see, for example, a regimen where an older patient might take a low-dose rapamycin (to target nutrient signaling) plus a senolytic once a year (to clear senescent cells), alongside periodic plasma exchange or a plasma-derived therapeutic to refresh the blood environment. Each addresses a different hallmark of aging – and together, they might produce a greater effect than any alone [62] [73]. Researchers are already exploring such **synergistic approaches**, as evidenced by companies using AI to find drug combos that hit multiple aging pathways at once [76] [63]. Future clinical trials will likely test multi-modal interventions, and the big question will be how much we can **extend healthspan** when these are deployed in concert. The dream scenario is adding healthy years (or decades) to life, *and* compressing the period of disability/disease at end of life to be as short as possible. Achieving that will dramatically change what it means to grow old.

- **From Longevity Science to Longevity Medicine:** The next steps also involve moving from lab evidence to **real-world impact**. That means developing practical protocols (e.g. how often should one get plasma exchange? what's the optimal rapamycin dosing schedule?) and proving cost-effectiveness. Longevity researchers like Dr. Eric Verdin of the Buck Institute stress building the clinical evidence base now: **"Most so-called 'longevity interventions' lack proven effectiveness in humans. By conducting clinical trials, we aim to change that"** [77]. The field is actively working to generate the data that healthcare authorities will require to approve therapies for age-related indication. If the trials demonstrate that an intervention safely reduces the risk of multiple diseases (for example, if a treatment makes a 70-year-old biologically resemble a 50-year-old and they indeed get fewer cancers, less dementia, better mobility), we could see **preventative geriatric medicine** take off in a new way. Doctors could prescribe an aging-slowing drug much like they do blood pressure or cholesterol meds today – not to treat one disease, but to holistically keep a patient

younger and healthier. The long-term impact on public health could be enormous: lower healthcare costs (because people aren't spending as many years with chronic illness), extended workforce participation, and improved quality of life for older individuals.

- **Accessibility and Global Impact:** A critical future goal is to ensure these advances benefit **everyone**, not just a select few. This involves policy and advocacy alongside the science – supporting research that seeks affordable interventions (such as peptides, small molecules, or lifestyle modifications informed by longevity science) and building frameworks for **compassionate use** or accelerated approval when appropriate. We are likely to see growing pressure to approve treatments that target aging, especially if early adopters in biohacker communities continue to self-experiment. This makes it all the more important to have solid clinical data and safety profiles. As aging researcher Dr. David Furman noted, this first wave of trials is just the start: *"Our findings show [an intervention] can impact age-related molecular changes. We are excited to expand our research to larger populations, increase access to these treatments for eligible patients, and continue to identify areas of unmet need where these therapies can make a meaningful difference."* [78] . In short, the coming years will be about scaling up ("larger populations"), reaching those who will benefit ("access"), and refining use-cases ("areas of unmet need" like specific diseases) as longevity moves from experiment to mainstream.

In conclusion, **the past week's breakthroughs showcase the rapid progress** in longevity science. Early-stage discoveries – from animals that don't age the way we do, to cells made young again – are illuminating new targets to attack. At the same time, translational research is bringing actual therapies (gene therapy, plasma exchange, geroprotective drugs) into clinical focus. The unifying theme is extending **healthspan**: keeping people functional, independent, and disease-free longer. Each incremental success builds the foundation for what was once thought impossible: treating aging itself. While true "immortality" remains a far-off ideal, the science of healthier, longer lives is advancing at an unprecedented pace, offering a glimpse of a future where seventy may truly be "the new fifty" – and the frailties of old age substantially deferred. The Immortality Update will continue to track these developments, as we witness the transformation of cutting-edge research into real-world longevity medicine.

Sources:

1. Steve Hill, "The 2025 Longevity Summit Dublin – Highlights," *Lifespan.io* (July 15, 2025) [79] [1] .
2. Steve Hill, "Longevity Summit Dublin Day 2 – New Therapies," *Lifespan.io* (July 15, 2025) [2] [12] .
3. Ophthalmology Times, "Life Biosciences' Partial Reprogramming for Vision Restoration," (Oct 22, 2024) [3] [7] .
4. Kathy Liszewski, "Scientists Are Turning Back the Clock," *Genetic Engineering & Biotechnology News* (June 13, 2025) [8] [76] .
5. Duke University, "Lemurs Age Without Inflammation – Can Humans Do the Same?" *SciTechDaily* (July 14, 2025) [27] [29] .
6. Susan R. Miller, "Study Suggests Lemurs Age Differently Than Humans," *Duke Today* (July 9, 2025) [31] [34] .
7. Stowers Institute, "Can Zebrafish Help Humans Regrow Hearing Cells?" *ScienceDaily* (July 14, 2025) [40] [46] .
8. Andrea Lius, "Regeneration Discovery May One Day Inform Hearing Loss Treatment," *The Scientist* (July 2025) [47] [42] .

9. Jessica Freeborn, “Rapamycin may extend lifespan as effectively as dietary restriction,” *Medical News Today* (June 23, 2025) [22] [21] .
10. University of East Anglia, “This Anti-Aging Drug Rivals Calorie Cutting for Longer Life,” *SciTechDaily* (June 26, 2025) [19] [26] .
11. Buck Institute & Circulate Health, “Therapeutic Plasma Exchange Reduces Biological Age,” *Mirage News* (May 29, 2025) [16] [78] .
12. *Rejuvenation Roundup June 2025*, Lifespan.io News (July 1, 2025) [52] [71] .
13. UCSF, “Midlife MRI spots rapid aging,” *ScienceDaily* (July 2, 2025) [66] .

---

[1] [2] [4] [5] [9] [10] [11] [12] [13] [14] [15] [18] [55] [72] [79] The 2025 Longevity Summit Dublin
https://www.lifespan.io/news/the-2025-longevity-summit-dublin/

[3] [6] [7] [49] [50] [51] Life Biosciences reports advances in nonhuman primate studies on partial epigenetic reprogramming for restoring visual function
https://www.ophthalmologytimes.com/view/life-biosciences-reports-advances-in-nonhuman-primate-studies-on-partial-epigenetic-reprogramming-for-restoring-visual-function

[8] [62] [63] [65] [73] [74] [76] Scientists Are Turning Back the Clock
https://www.genengnews.com/topics/translational-medicine/scientists-are-turning-back-the-clock/

[16] [17] [77] [78] Plasma Exchange Proven to Reverse Biological Aging | Mirage News
https://www.miragenews.com/plasma-exchange-proven-to-reverse-biological-1468308/

[19] [20] [24] [25] [26] [70] This Anti-Aging Drug Rivals Calorie Cutting for Longer Life, Study Finds
https://scitechdaily.com/this-anti-aging-drug-rivals-calorie-cutting-for-longer-life-study-finds/

[21] [22] [23] [54] Longevity: Can rapamycin extend lifespan? What latest research says
https://www.medicalnewstoday.com/articles/rapamycin-may-extend-lifespan-as-effectively-as-dietary-restrictions

[27] [29] [30] [33] [36] Lemurs Age Without Inflammation – Can Humans Do the Same?
https://scitechdaily.com/lemurs-age-without-inflammation-can-humans-do-the-same/

[28] [35] [37] [75] Lemurs age without inflammation—and it could change human health forever | ScienceDaily
https://www.sciencedaily.com/releases/2025/07/250710113146.htm

[31] [32] [34] Study Suggests Lemurs Age Differently Than Humans | Duke Today
https://today.duke.edu/2025/07/study-suggests-lemurs-age-differently-humans

[38] Lemur Study Offers Insights into Inflammaging in Humans | Biocompare: The Buyer's Guide for Life Scientists
https://www.biocompare.com/Life-Science-News/620294-Lemur-Study-Offers-Insights-into-Inflammaging-in-Humans/

[39] [40] [41] [44] [46] Can zebrafish help humans regrow hearing cells? | ScienceDaily
https://www.sciencedaily.com/releases/2025/07/250714052110.htm

[42] [43] [45] [47] [48] Regeneration Discovery May One Day Inform Hearing Loss Treatment | The Scientist
http://www.the-scientist.com/regeneration-discovery-may-one-day-inform-hearing-loss-treatment-73171

[52] [53] [68] [69] [71] Rejuvenation Roundup June 2025 | Lifespan Research Institute
https://www.lifespan.io/news/rejuvenation-roundup-june-2025/

[56] [57] [58] [59] [60] [61] Researchers Find Age-Modulatory Perturbations at Scale
https://www.lifespan.io/news/researchers-find-age-modulatory-perturbations-at-scale/

64 Single-cell immune aging clocks reveal inter-individual ...
https://pmc.ncbi.nlm.nih.gov/articles/PMC12003178/

66 67 Healthy Aging News -- ScienceDaily
https://www.sciencedaily.com/news/health_medicine/healthy_aging/